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Lisette Okkels Jensen, MD, PHD,* Michael Maeng, MD, PHD,† Anne Kaltoft, MD, PHD,†
Per Thayssen, MD, DMSCI,* Hans Henrik Tilsted Hansen, MD,‡ Morten Bottcher, MD, PHD,†
Jens Flensted Lassen, MD, PHD,† Lars Romer Krussel, MD, DMSCI,†
Klaus Rasmussen, MD, DMSCI,‡§ Knud Noerregaard Hansen, MD,* Lars Pedersen, MSC,
Soeren Paaske Johnsen, MD, PHD,§ Henrik Toft Soerensen, MD, DMSCI, PHD,¶
Leif Thuesen, MD, DMSCI†
Odense, Aarhus, and Aalborg, Denmark; and Boston, Massachusetts
Objectives The aim of the study was to examine outcomes subsequent to implantation of drug-eluting stents (DES) and
bare-metal stents (BMS).
Background Use of DES might be associated with increased risk of stent thrombosis (ST), myocardial infarction (MI), and
death.
Methods From January 2002 through June 2005, data from all percutaneous coronary interventions in western Denmark
were prospectively recorded in the Western Denmark Heart Registry; 12,395 consecutive patients (17,152 le-
sions) treated with stent implantation were followed for 15 months. Data on death and MI were ascertained
from the national databases. The Academic Research Consortium definition of ST was used.
Results The DES were implanted in 3,548 patients (5,422 lesions) and BMS were implanted in 8,847 patients (11,730
lesions). Definite, probable, or possible ST was found in 190 (2.15%) patients in the BMS group and in 64
(1.80%) patients in the DES. The risk of definite ST was similar in the 2 groups (DES: 0.65%; BMS: 0.61%). Very
late definite ST (between 12 and 15 months after implantation) occurred more frequently in patients receiving
DES (hazard ratio [HR] 10.93, 95% confidence interval [CI] 1.27 to 93.76). Also, the risk of MI between 12 and
15 months after implantation was higher in the DES group (HR 4.00, 95% CI 2.06 to 7.79). Mortality was similar
in the 2 groups. Target lesion revascularization was reduced by 43% in patients treated with DES (HR 0.57, 95%
CI 0.48 to 0.67).
Conclusions The minor risk of ST and MI within 15 months after implantation of DES seems unlikely to outweigh the benefit of
these stents. (J Am Coll Cardiol 2007;50:463–70) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.002s
a
R
a
t
(
t
U
s
s
B
A
coronary drug-eluting stent (DES) implantation is increas-
ngly used for coronary revascularization. In patients with
oronary artery disease, randomized controlled trials have
onsistently linked DES with reduction of neointimal hy-
erplasia, decreased risk of restenosis, and less frequent need
or repeated revascularization, compared with bare-metal
rom the *Department of Cardiology, Odense University Hospital, Odense, Den-
ark; †Department of Cardiology, Skejby Sygehus University, Aarhus, Denmark;
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Den-
ark; ‡Department of Cardiology, §Center of Cardiovascular Research, Aalborg
ospital, Aarhus University Hospital, Aalborg, Denmark; and the ¶Department of
pidemiology, Boston University, Boston, Massachusetts.i
Manuscript received April 4, 2007; revised manuscript received May 21, 2007,
ccepted June 3, 2007.tents (BMS) (1–4). The beneficial effects of DES were
chieved without raising any safety concerns initially (5).
ecent studies, including a post hoc analysis, a meta-
nalysis of randomized trials of DES, and a large observa-
ional study, reported increased risks of stent thrombosis
ST), myocardial infarction (MI), and death associated with
he use of this type of stent (6–9). In December 2006, the
.S. Food and Drug Administration (FDA) issued a
tatement concluding that, on the basis of available data, the
mall increase in the risk of ST with DES, compared with
MS, did not confer an increased risk of death or MI (10).
ccording to the FDA, the lack of an observed association
ould be explained either by insufficient numbers of patients
n currently available studies or by deaths or MIs being offset
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Coronary Stent and Stent Thrombosis July 31, 2007:463–70by a reduction in the rate of
events associated with in-stent
restenosis and with additional re-
vascularization procedures. In
contrast, 2 recently randomized
trials demonstrated no increased
risk with DES compared with
BMS in terms of long-term sur-
vival and survival free of MI and
ST (11,12).
We compared rates of ST, MI,
death, and target lesion revascu-
larization (TLR) after implanta-
tion of DES and BMS, with
population-based medical data-
bases in Denmark.
ethods
etting and design. We performed this 15-month follow-up
tudy with western Denmark’s health care databases, cover-
ng the region’s entire population (approximately 3 million
nhabitants; 55% of the Danish population). All patients
ere followed for 15 months. The Danish National Health
ervice provides universal tax-supported health care, guar-
nteeing free access to general practitioners and hospitals,
hile refunding variable proportions of prescription medi-
ation costs. Our data came from the sources described in
he following text.
ANISH CIVIL REGISTRATION SYSTEM. This system has
ept electronic records on gender, date of birth, residence,
ate of emigration, and changes in vital status since 1968
13). Information on vital status is updated daily. The
ecords include a unique 10-digit civil registration number,
hich is assigned at birth and is used in all public registries,
llowing accurate record linkage.
ATIONAL REGISTRY OF CAUSES OF DEATHS. This registry
as collected data on dates and causes of death since 1973.
ATIONAL PATIENT REGISTRY. This registry, established in
977, collects data on all non-psychiatric hospital stays at
anish hospitals, including dates of admission and dis-
harge, surgical procedure(s), and up to 20 discharge diag-
oses assigned by the treating physician and coded accord-
ng to the International Classification of Diseases (8th
evision [ICD-8] until the end of 1993 and 10th revision
ICD-10] thereafter) (14).
ESTERN DENMARK HEART REGISTRY. This regional reg-
stry, established in 1999, collects detailed patient and
rocedure data for all interventions carried out in western
enmark’s 3 coronary intervention centers (Odense Uni-
ersity Hospital, Aarhus University Hospital [Skejby], and
arhus University Hospital [Aalborg]) (15,16).
atients and procedures. With the Western Denmark
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
FDA  Food and Drug
Administration
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosis
TLR  target lesion
revascularizationeart Registry, we identified all percutaneous coronary inter- Nentions (PCIs) performed from January 1, 2002, through June
0, 2005. We included the patients’ first PCI occurring during
he study period (the index procedure) and were further
estricted to patients who received either a BMS or a DES.
atients with a PCI before the study period were not excluded.
hose treated by balloon angioplasty without stent implanta-
ion or by a combination of BMS and DES were excluded.
Percutaneous coronary intervention was performed ac-
ording to the standard practices of the participating cen-
ers. The post-intervention antiplatelet regimen included
ifelong acetylsalicylic acid (75 to 150 mg once daily) and
lopidogrel with a loading dose of 300 mg followed by
aintenance with 75 mg daily. The recommended duration
f clopidogrel treatment was 3 to 12 months until Novem-
er 2002 and 12 months thereafter. In patients with definite
T, we reviewed medical records from the hospital admis-
ion to verify the use of antiplatelet therapy.
nd points. The primary end point was ST (definite,
robable, or possible). Secondary end points were all-cause
ortality, cardiac death, MI, and TLR. All end points were
ssessed within 15 months of the date of PCI and were
scertained from the Western Denmark Heart Registry, the
ational Patient Registry, and the National Registry of
auses of Deaths. All relevant records were reviewed by a
pecialist committee, which adjudicated the end points. In
he case of ST, the medical records were retrieved and the
atheterization films were reviewed.
We defined ST using the Academic Research Consortium
ARC) definition, with a modification for probable ST (17).
EFINITE ST. Angiographic confirmation of ST and at least
of the following signs present within 48 h: new onset of
schemic symptoms at rest, new electrocardiographic
hanges suggestive of acute ischemia, or typical rise and fall
n cardiac biomarkers.
ROBABLE ST. Any unexplained death within the first 30
ays after intracoronary stenting.
OSSIBLE ST. Any unexplained death occurring from 30
ays after intracoronary stenting until the end of the
ollow-up period.
Stent thrombosis was further characterized as acute (0 h
o 24 h), subacute (1 day to 30 days), late (30 days
o 1 year), and very late (1 year to 15 months).
Admissions and readmissions for MI (ICD-10 codes I21
o I21.9) were ascertained from the National Patient Reg-
stry (13). New MIs were defined as admissions with a MI
ccurring 28 days after the index PCI (18).
We ascertained deaths from the Danish Civil Registra-
ion System and then reviewed original death certificates
btained from the National Registry of Causes of Deaths.
eaths were classified according to their underlying causes,
s recorded on the death certificate.
Target lesion revascularization within 15 months after
he index stent implantation was ascertained from the
ational Heart Registry and defined as a repeat PCI of the
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July 31, 2007:463–70 Coronary Stent and Stent Thrombosisndex lesion or coronary artery bypass grafting (CABG).
epeat PCI or CABG of study patients in hospitals outside
he study region virtually did not take place.
ovariates. We retrieved data from the Western Denmark
eart Registry on a wide range of potential predictors for
ubsequent cardiovascular disease, including characteristics
f the patients, procedures, and lesions. For each patient, we
btained data on all discharge diagnoses from the National
atient Registry from 1977 until the date of implantation.
e then computed the Charlson comorbidity index (19),
hich covered 19 major disease categories, including diabe-
es mellitus, heart failure, cerebrovascular diseases, and
ancer. The index value was a weighted summary of the
iagnoses, with each weight calculated on the basis of 1-year
ortality associated with each disease in the original Charl-
on dataset (19).
Data on all essential patient and procedure characteristics
ere95% complete, and ascertainment of end points (ST,
eath, and MI) was 100% complete.
tatistical methods. We counted end point events that
ccurred during the follow-up period and compared their
ates between the cohort of patients with DES and the
ohort with BMS. Follow-up began on the date of the index
CI procedure. In analyses with ST as the outcome,
ollow-up continued until date of definite ST, death, or
migration, or after 15 months of follow-up, whichever
ame first. In analyses with death as the outcome, follow-up
atient and Procedure Characteristics in Patients Treated With DEr BMS in Western D nm rk From January 2002 Th ough June 200
Table 1 Patient and Procedure Characteristics in Patients Treaor BMS in Western Denmark From January 2002 Throu
Number of patients
Male gender, n (%)* 6,37
Age, yrs† 6
Family history, n (%)* 3,19
Smoking, n (%)* 3,06
Diabetes mellitus, n (%)* 87
Hypertension, n (%)* 3,06
Previous coronary artery bypass grafting, n (%)* 48
Previous percutaneous coronary intervention, n (%)* 73
Previous myocardial infarction, n (%)* 2,33
Lipid-lowering therapy, n (%)* 3,32
Procedure time, min‡ 22.
Flouroscopy time, min‡ 7.
Contrast, ml‡ 125.
Number of treated lesions, n‡ 1.
Indication for percutaneous coronary intervention*
Stable angina, n (%) 2,97
Non–ST-segment elevation MI/unstable angina, n (%) 2,71
ST-segment elevation MI, n (%) 2,94
Other, n (%) 21
Comorbidity index score, n (%)*
0 4,58
1–2 3,44
3 81Comparison made using chi-square test. †Mean (standard deviation); comparison made using t test. ‡M
BMS  bare-metal stents; DES  drug-eluting stents; MI  myocardial infarction.ontinued until date of death or emigration, or after 15
onths of follow-up. In analyses with MI as the outcome,
ollow-up continued until date of MI, death, or emigration,
r after 15 months of follow-up.
We constructed Kaplan-Meier curves for patients and
esions treated with DES or BMS. We used the life-table
ethod to compute the 15-month cumulative incidence for
ach end point (proportion of the population at risk with the
utcome of interest).
Cox proportional hazards regression was used to compute
azard ratios (HRs) as estimates for each end point. Because
he hazards were not proportional throughout the follow-up
eriod, we computed the estimates of HRs within separate
ime windows, where the proportionality assumption held.
he HRs in these subanalyses reflected the risk among
atients alive and at risk for the specific end point at the
tart of each time period (e.g., at 30 days or 1 year of
ollow-up). We controlled for age, gender, PCI indication,
nd procedure time in all regression analyses. To improve
recision of the risk estimates, we used the change-in-
stimate method, which entailed retaining variables that
hanged HR estimates for an outcome by more than 10%
20). Thus, in the lesion-specific analyses (ST and TLR) we
lso adjusted for diabetes mellitus, stent length, and refer-
nce vessel size. Distributions of continuous variables in the
groups were compared with either the 2-sample t test or
he Mann-Whitney test according to whether data followed
ith DES
ne 2005
S DES p Value
7 3,548
) 2,565 (72.3) 0.79
11.4 61.7  11.2 0.001
) 1,425 (40.2) 0.001
) 1,195 (33.7) 0.10
552 (15.6) 0.001
) 1,420 (40.0) 0.001
240 (6.8) 0.003
346 (9.8) 0.006
) 802 (22.6) 0.001
) 1,761 (49.6) 0.001
–35.0) 25.0 (15.0–40.0) 0.001
12.4) 8.2 (5.0–14.1) 0.001
–200.0) 130 (90.0–200.0) 0.002
2.0) 1.0 (1.0–2.0) 0.001
0.001
) 1,614 (45.5)
) 1,055 (29.7)
) 764 (21.5)
115 (3.2)
0.001
) 1,761 (49.6)
) 1,367 (38.5)
420 (11.8)S5
ted W
gh Ju
BM
8,84
5 (72.1
4.2 
1 (36.1
4 (34.6
1 (9.9)
2 (34.6
3 (5.5)
9 (8.4)
8 (26.4
2 (37.6
0 (15.0
3 (4.2–
0 (90.0
0 (1.0–
4 (33.6
0 (30.6
6 (33.3
7 (2.5)
6 (51.8
5 (38.9
6 (9.2)edian (25% to 75% percentiles); comparison made using Mann-Whitney test.
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Coronary Stent and Stent Thrombosis July 31, 2007:463–70he normal distribution. Distributions of categorical vari-
bles were compared with the chi-square test. We analyzed
ata with the SAS software version 9.13 (SAS Institute Inc.,
ary, North Carolina).
esults
escriptive data. The study encompassed 12,395 consec-
tive patients with 17,152 lesions. Of these, 8,847 patients
ith 11,730 lesions were treated with BMS and 3,548
atients with 5,422 lesions received DES (Cypher n 
,429 [63.2%], and Taxus n  1,993 [36.8%]). The pa-
ients’ mean age was 63.5  11.4 years; 15.9% of the
atients were older than 75 years, and 11.5% suffered from
iabetes mellitus. The indications for PCI were ST-
egment elevation MI (29.9%), non–ST-segment elevation
I/unstable angina (30.4%), stable angina (37.0%), and
ther (2.7%). Baseline patient and procedure characteristics
Table 1) and lesion characteristics (Table 2) differed
ubstantially between the groups treated with BMS versus
ES.
T. DEFINITE ST. Overall rates of definite ST were similar
or patients treated with BMS (n  71; cumulative inci-
ence, 0.65%) and DES (n  35; cumulative incidence,
.61%), p 0.78 (chi-square test). Rates of acute, subacute,
nd late definite ST were also similar in the 2 groups (Fig.
A). Very late definite ST occurred in 1 patient (cumulative
ncidence  0.01%) in the BMS group and in 5 patients
cumulative incidence, 0.09%) in the DES group (adjusted
R 10.93; 95% confidence interval [CI] 1.27 to 93.76; p 
Lesions Treated With DES or BMS inWestern D nmark, January 2002 Through June
Table 2 Lesions Treated With DES or BMS iWestern Denmark, January 2002 Th
Number of lesions, n 1
Vessel*
Right coronary artery, n (%) 4,684
Left anterior descending artery, n (%) 4,258
Left circumflex artery, n (%) 2,680
Left main, n (%) 98
Sapheneous vein graft, n (%)* 134
Lesion length, mm† 12.0
Lesion type, n (%)*
A 2,554
B1 6,908
B2 1,312
C Tc 948 (8.1) 1,585
Restenotic lesion, n (%)* 118
Stent length, mm† 15.0
Stent number, n† 1.0
Max balloon pressure, atm† 15.0
Max balloon diameter, mm† 3.5
Reference segment, mm† 3.3
Minimum lumen diameter, mm† 0.3
Stenosis, % of luminal diameter† 90.0*Comparison made using chi-square test. †Median (25% to 75% percentiles)
Abbreviations as in Table 1..03) (Table 3). None of the 106 cases of definite ST
ccurred in saphenous vein grafts.
EFINITE, PROBABLE, OR POSSIBLE ST. Definite, probable,
r possible ST was found in 190 (cumulative incidence,
.15%) patients treated with BMS and in 64 (cumulative
ncidence, 1.80%) patients treated with DES (HR 0.83;
5% CI 0.63 to 1.12; p  0.20) (Fig. 1B). After adjusting
or covariates, the risk of ST (definite, probable, or possible)
id not differ between the 2 groups (adjusted HR 0.91; 95%
I 0.67 to 1.24; p  0.57) (Table 4). Late possible ST (i.e.,
eyond 1 year of follow-up) occurred in 11 patients treated
ith BMS and 1 patient treated with DES (adjusted HR
.70; 95% CI 0.15 to 3.56; p  0.65).
REDICTORS OF DEFINITE ST. ST-segment elevation MI
adjusted HR 3.80; 95% CI, 1.97 to 5.46; p  0.001), stent
ength (adjusted HR 1.03; 95% CI 1.01 to 1.05; p 0.001),
nd procedure time (adjusted HR 1.01; 95% CI 1.00 to
.02; p  0.001) increased the risk of definite ST.
EFINITE ST AND ANTIPLATELET THERAPY. Among the
06 patients who developed definite ST, 85.8% (n  91)
eceived treatment with dual antiplatelet therapy (aspirin
nd clopidogrel) at the time of the thrombotic event. In the
patients with very late ST, 2 patients were receiving dual
ntiplatelet therapy, 3 patients were treated with aspirin
nly, and 1 patient had discontinued both aspirin and
lopidogrel after 12 months treatment.
ortality. All-cause 15-month mortality was 5.7% and
as higher among patients with BMS than among patients
h June 2005
DES p Value
5,422
0.001
1,385 (25.5)
2,815 (51.9)
1,034 (19.1)
188 (3.5)
78 (1.4) 0.367
16.0) 14.0 (10.0–20.0) 0.001
0.001
1,149 (21.2)
2,171 (40.0)
517 (9.54)
129 (2.4) 0.001
18.0) 18.0 (13.0–24.0) 0.001
.0) 1.0 (1.0–1.0) 0.001
18.0) 15.0 (14.0–18.0) 0.001
.8) 3.3 (3.0–3.7) 0.001
.7) 3.1 (2.9–3.5) 0.001
.7) 0.3 (0.0–0.7) 0.05
99.0) 90.0 (80.0–99.0) 0.312005
n
roug
BMS
1,730
(39.9)
(36.3)
(22.9)
(0.8)
(1.1)
(10.0–
(21.8)
(58.9)
(11.2)
(29.2)
(1.0)
(12.0–
(1.0–1
(12.0–
(3.0–3
(3.0–3
(0.0–0
(88.0–; comparison made using Mann-Whitney test.
w
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July 31, 2007:463–70 Coronary Stent and Stent Thrombosisith DES (6.2% vs. 4.4%; p 0.001) (chi-square test) (Fig.
C). After adjustment for covariates, this disparity disap-
eared (adjusted HR 0.90; 95% CI 0.75 to 1.09; p  0.29).
Figure 1 Clinical Outcome
(A) Definite stent thrombosis (ST). Risk of definite ST among patients treated with
probable, and possible ST among patients treated with BMS or DES. (C) All-cause
infarction (MI). Risk of MI among patients treated with BMS or DES.
isk of Definite Stent Thrombosis in Lesions Treated With BMS (n
Table 3 Risk of Definite Stent Thrombosis in Lesions Treated W
BMS
No. of
Events
No./100
Person-Yrs
No.
Eve
All 71 0.5 3
Acute (24 h) 12 37.5
1 day to 30 days 46 4.9 1
30 days to 12 months 12 0.1
12 months 1 0.04Adjusted for age, gender, clinical indication, stent length, and procedure time.
Abbreviations as in Table 1.ll-cause mortality 12 to 15 months after initial stenting
as nearly similar in the 2 groups (adjusted HR 1.11; 95%
I 0.62 to 1.99; p  0.22). Overall 15-month cardiac
metal stents (BMS) or drug-eluting stents (DES). (B) Overall ST. Risk of definite,
lity. All-cause mortality among patients treated with BMS or DES. (D) Myocardial
,730) or DES (n  5,422) in Western Denmark
MS (n  11,730) or DES (n  5,422) in Western Denmark
DES
Hazard Ratio*
(95% Confidence Interval) p Value
No./100
Person-Yrs
0.5 0.93 (0.60–1.46) 0.76
54.1 0.94 (0.33–2.67) 0.90
3.4 0.69 (0.38–1.27) 0.23
0.2 0.93 (0.35–2.89) 1.00
0.4 10.93 (1.27–93.76) 0.029bare-
morta 11
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Coronary Stent and Stent Thrombosis July 31, 2007:463–70ortality was 3.4%, with higher cardiac mortality among
MS patients than among DES patients (3.8% vs. 2.4%)
HR 0.63; 95% CI 0.50 to 0.80; p  0.002). After
djustment, risk of cardiac death no longer differed in the 2
roups (adjusted HR 0.88; 95% CI 0.68 to 1.13; p  0.31).
he non-cardiac 15-month cumulative mortality was 2.2%
nd was similar among BMS (2.3%) and DES (1.9%) stent
atients (HR 0.81; 95% CI 0.61 to 1.06; p  0.12).
ovariate adjustment did not change this result (adjusted
R 0.95; 95% CI 0.71 to 1.27; p  0.71).
I. The 15-month cumulative incidence of MI was
imilar in the 2 stent groups (3.2% [DES] vs. 3.0%
BMS]; p  0.65). However, from 12 to 15 months after
he index stent implantation, MI occurred in 0.64% of
atients treated with DES versus 0.22% of patients
reated with BMS (HR 3.13; 95% CI 1.69 to 5.79; p 
.001) (Fig. 1D). The association became stronger after
djustment for covariates (adjusted HR 4.00; 95% CI
.06 to 7.79; p  0.0001).
LR. Target lesion revascularization within 15 months
ccurred less frequently in DES patients than in BMS
atients (cumulative incidence, 4.6% vs. 7.1%; p  0.0001).
fter adjustment for age, gender, clinical presentation,
iabetes mellitus, stent length, and reference vessel size, the
isk reduction was 43% (adjusted HR 0.57; 95% CI 0.48 to
.67; p  0  0.001). Diabetes mellitus (adjusted HR 1.31;
5% CI 1.09 to 1.58; p 0.005), ST-segment elevation MI
adjusted HR 1.41; 95% CI 1.19 to 1.66; p  0.0001), and
tent length (adjusted HR 1.02; 95% CI 1.01 to 1.03; p 
.001) increased the risk of TLR within 15 months, whereas
ize of the reference vessel was inversely related to the risk
f TLR (adjusted HR 0.69; 95% CI 0.61 to 0.79; p 
elative Risk Estimates for Death, Myocardial Infarction and Stentnd Possible) Among Patients Treated With BMS (n  8,847) or D
Table 4 Relative Risk Estimates for Death, Myocardial Infarctioand Possible) Among Patients Treated With BMS (n 
Patients With BMS
No. of
Events
No./100
Person-Yrs
N
E
All-cause death 551 5.2
12 months 503 22.6
12 months 48 0.6
Cardiac 335 3.2
Noncardiac 207 2.0
Myocardial infarction 256 2.6
28 days to 12 months 238 3.1
12 months 18 0.9
Overall stent thrombosis 190 1.8
Acute (24 h) 23 95.6
1 day to 30 days 98 13.9
30 days to 12 months 57 0.7
12 months 12 0.6
Probable stent thrombosis 67 9.4
Possible stent thrombosis 57 0.6
Adjusted for age, gender, clinical indication, and procedure time.
Abbreviations as in Table 1..001). eiscussion
n this population-based study we found that BMS and
ES treatments were associated with low rates of cardiac
vents within 15 months after their implantation. The
verall rates of ST, MI, and death were similar among the
atients treated with the 2 stent types. Furthermore, use of
ES reduced the risk of clinically necessary TLR by 43%.
The incidence rate of definite ST in our study was similar
o that reported in a meta-analysis (5) of 10 randomized
tudies with 9 to 12 months of follow-up that compared
ES and BMS. It was also comparable to the results of the
-Cypher Registry (21). Our findings, however, differed
rom those of the BASKET-LATE (BAsel Stent Kosten
ffektivitäts Trial—LAte Thrombotic Events) study (6), in
hich there was a higher overall rate of ST. Furthermore,
atients treated with DES experienced an earlier and
ncreased occurrence of ST compared with patients with
MS than found in our study. This might be related to the
onger duration of dual antiplatelet therapy in our study.
his might also explain the lower risk of ST among DES
atients in our study as compared with a patient-level
eta-analysis presented at a December 2006 FDA hearing
10) and a recently published registry study on sirolimus-
nd paclitaxel-eluting stents (22).
Data from the Swedish Coronary Angiography and
ngioplasty Registry showed rates of mortality and MI
imilar to those in our study (7). These registry data
uggested that rates of death and MI were similar for
atients with DES and BMS during the first 6 months after
tent implantation. After 6 months, both mortality and MI
ates increased in the DES group. Our finding of a minor
mbosis (Definite, Probable, 3,548) in Western Denmark
d Stent Thrombosis (Definite, Probable,
7) or DES (n  3,548) in Western Denmark
tients With DES
Hazard Ratio* (95%
Confidence Interval) p Value
No./100
Person-Yrs
3.6 0.90 (0.75–1.09) 0.29
15.6 0.88 (0.73–1.08) 0.22
0.4 1.11 (0.62–1.99) 0.74
2.0 0.88 (0.68–1.13) 0.31
1.6 0.95 (0.71–1.27) 0.71
2.8 1.14 (0.89–1.45) 0.31
2.8 0.94 (0.72–1.34) 0.67
2.8 4.00 (2.06–7.79) 0.001
1.5 0.91 (0.67–1.24) 0.57
82.6 0.64 (0.26–1.53) 0.31
8.4 0.73 (0.45–1.18) 0.20
0.8 1.19 (0.72–1.96) 0.50
0.7 1.78 (0.65–4.91) 0.26
3.8 0.51 (0.26–1.01) 0.05
0.5 1.11 (0.65–1.89) 0.70ThroES (n
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ifference between the 2 groups in cardiac or non-cardiac
ortality during 15 months of follow-up.
For most of our study period, the recommended duration
f clopidogrel treatment was 12 months. This potentially
owered rates of ST, both in patients treated with DES and
hose treated with BMS. Thus, our data support the recent
DA recommendation for prolongation of antiplatelet ther-
py (10). Several studies have linked the risk of ST to
iscontinuation of clopidogrel treatment among patients
ith DES (23,24). It is notable that in our study the
umber of definite stent thromboses and acute MI events in
atients with DES increased significantly after 12 months,
ven though the absolute event count was small.
We identified ST-segment elevation MI as a predictor of
efinite ST. As found in 2 recent randomized trials (25,26),
T-segment elevation MI did not affect the magnitude of
he relative risk significantly when patients with the 2 stent
ypes were compared.
tudy limitations. Observational studies should be scruti-
ized for potential biases. Our relative risk estimates are
ased on population-based data, largely ruling out referral
nd diagnostic biases. Still, our study has limitations,
ncluding potential unmeasured confounding and bias due
o lack of blinding. However, adjustment for the most
mportant predictors of cardiovascular events reduced the
ikelihood of severe residual confounding by indication.
Our data were collected over a 3-year period, during
hich the proportion of DES increased from 0% to 75% of
ll stent implantations. To minimize study bias during this
ime of transition, we provided 15 months of follow-up data
or all patients. Also, we reported recommended 12-month
uration for antiplatelet combination treatment, although
he actual duration of treatment with dual anti-platelet
gents was only available for patients with definite ST.
nother concern is that we were unable to group patients
ith MI by area of infarction and therefore could not
nclude MI in the ARC definition of probable ST. With the
RC definition of probable and possible ST, any unex-
lained death is categorized as ST. Although this situation
s attributable to some acute events, most likely thrombosis,
t is not invariably associated with all cases of unexplained
eath. Finally, the follow-up time of 15 months, although
onger than in most other studies, might still be inadequate
o fully quantify possible risks associated with use of DES.
onclusions
uring the 15 months after stent implantation, overall rates
f ST, MI, and death were low and of similar order of
agnitude in patients receiving BMS or DES and dual
ntiplatelet therapy for 12 months. After 12 months, there
as a small but significant excess of definite stent throm-
oses in the group with DES. Our findings lend support to
he recommendation of at least 12 months of dual antiplate-et therapy for patients treated with DES. Our study also
uggests that the low risk of ST and MI within 15 months
fter implantation of DES does not outweigh the benefit of
hese stents, materializing in a marked reduction in the risk
f clinically driven TLR.
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